Clinical Trials Logo

Muscular Atrophy, Spinal clinical trials

View clinical trials related to Muscular Atrophy, Spinal.

Filter by:

NCT ID: NCT04851873 Completed - Clinical trials for Spinal Muscular Atrophy

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

SMART
Start date: September 8, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene weighing ≥ 8.5 kg and ≤ 21 kg, over a 12 month period.

NCT ID: NCT04718181 Completed - Clinical trials for Muscular Atrophy, Spinal

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.

NCT ID: NCT04674618 Completed - Ultrasound Clinical Trials

Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen

Start date: December 14, 2020
Phase: N/A
Study type: Interventional

Intrathecal administration of Nusinersen, an antisense oligonucleotide capable of increasing Survival Motor Neuron protein production, has been tested in Spinal Muscular Atrophy (SMA) to improve motor function and survival. A feature of adult SMA patients is a progressive neuromyopathic scoliosis, so spinal nusinersen administration can be challenging. Landmark identification using a pre-procedure ultrasound (US) facilitates technical performance of spinal anesthesia and allows for the elimination of radiation exposure. The aim of this randomized prospectic study is to determine if the US assistance for spinal administration of nusinersen is able to increase the proportion at successful 1st needle insertion of the needle. Secondary outcome measures are procedure time, patient satisfaction and prevalence of postdural puncture headache. Patients will be randomlized to receive a US-assisted nusinersen administration or a landmark based nusinersen administration.

NCT ID: NCT04602195 Completed - Clinical trials for Spinal Muscular Atrophy

Responsiveness and Validation Study of MFM-32 in SMA Patients Treated With Nusinersen

NusiMFM
Start date: January 19, 2021
Phase:
Study type: Observational

The Motor Function Measure (MFM), a reliable tool assessing motor function and its progression in most neuromuscular diseases, is widely used in France in many teams. It can be used regardless of the severity of the motor impairment or the ambulatory status of the patient, allowing its use throughout the whole follow-up period of the patient, even in case of the loss of walking. Two versions of the MFM exist, one composed of 32 items originally validated for patients from 6 years old (MFM-32) and a shorter version composed of 20 items originally validated for patients between 2 and 6 years old (MFM-20). In order to prove the possible use of MFM-32 as early as the age of 2 years to validly and reliably monitor the evolution of the motor function of children treated with Nusinersen, we propose in this project to study the sensitivity to treatment-induced change of MFM-32 and the validity of the scale in this population.

NCT ID: NCT04591678 Completed - Clinical trials for Spinal Muscular Atrophy

Adults With SMA Treated With Nusinersen

Start date: October 1, 2018
Phase:
Study type: Observational

This is a single center, 22-month observational study of nusinersen treatment in adult patients with spinal muscular atrophy (SMA). There will be a total of seven visits. Nusinersen is provided as standard of care and not considered research in this study. Information will be collected regarding the general health, and function including muscle strength of, as well as any positive and/or adverse events experienced by the study participants.

NCT ID: NCT04587492 Completed - Clinical trials for Spinal Muscular Atrophy

Metabolomics of Children With SMA

Start date: January 1, 2017
Phase:
Study type: Observational

The aim of the proposed project is to evaluate whether the metabolome of patients with spinal muscular atrophy (SMA) before the initiation of treatment with nusinersen differs from the metabolome of healthy individuals and whether it changes 14 months after treatment with nusinersen.

NCT ID: NCT04419233 Completed - Clinical trials for Muscular Atrophy, Spinal

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection

PANDA
Start date: November 18, 2020
Phase:
Study type: Observational

The primary objective of this study is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in China.The secondary objectives are to collect data on the efficacy and the pharmacokinetics of nusinersen sodium injection in the post-marketing setting in China.

NCT ID: NCT04404764 Completed - Clinical trials for Spinal Muscular Atrophy

Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study

Start date: May 27, 2020
Phase:
Study type: Observational [Patient Registry]

This study aims to characterize the clinical-epidemiological profile and baseline characteristics of patients with spinal muscular atrophy (SMA) 5q types II and III in follow-up at the Brazilian Unified Public Health System (SUS). The study data will be based on patients´ medical records from several Brazilian public hospitals, which will be defined by the Brazilian Ministry of Health (MS).

NCT ID: NCT04335942 Completed - Clinical trials for Duchenne Muscular Dystrophy

Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor

Es-Alert
Start date: September 30, 2021
Phase: N/A
Study type: Interventional

Spinal cord injuries and people with Duchenne Muscular Dystrophy or Infant Spinal Muscular Atrophy (ISA) are prone to pain and pressure sores associated with prolonged sitting. For this reason, it is recommended that people with spinal cord injuries release pressure every 15 to 30 minutes and motorized wheelchair users use the electric positioning functions at least 1 minute every hour. The aim is to prevent and/or reduce pain and pressure sores. These devices could help to observe daily the variability of users' pressure maps, their impact on occupational performance, the link with pain and redness and could propose customized adjustments.

NCT ID: NCT04228718 Completed - Clinical trials for Spinal Muscular Atrophy

The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs

Start date: July 1, 2019
Phase:
Study type: Observational

The purpose of this study is to assess carer burden, needs, and expectations of Spinal Muscular Atrophy Parents